Skip to main content

Table 1 Population descriptive

From: Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease

  ACE cohort Heidelberg/Mannheim cohort P value of difference
MCI patients (N) 142 40  
Metabolomics profiling tissue CSF and plasma CSF  
Age (SD) blood collection, years 71.94 (7.74) 68.85 (8.50) 0.042
Female (%) 74 (52%) 22 (55%) 0.747
Body mass index (SD) 26.46 (3.74) 25.85 (3.61) 0.353
Lipid-lowering medication user (%) 63 (44%) 11 (27%) 0.055
Amyloid-beta 42 in pg/mL (SD) 791.59 (337.36) 690.84 (397.13) 0.151
P-Tau in pg/mL (SD) 71.37 (37.30) 63.17 (29.96) 0.153
Total tau in pg/mL (SD) 478.82 (253.45) 380.95 (326.97) 0.124
MMSE 24.93 (4.07) 26.55 (2.51) 2.67 × 10−3
CDR 0.50 (0.06) 0.55 (0.15) 0.047
APOE genotype N (%)
APOE 44/34/24 50 (35%) 18 (45%)  
APOE 33 81 (57%) 18 (45%)  
APOE 22/23 11 (8%) 4 (10%)  
  1. Abbreviations: MCI mild cognitive impairment, SD standard deviation, CSF cerebrospinal fluid, MMSE the Mini-Mental State Examination, CDR clinical dementia rating, APOE apolipoprotein E gene